Please try another search
Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patient health. The company’s medicines address the unmet medical needs of patients in the areas of anti-HIV treatment and pain management. It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS. The company’s products in development include FB1002, an all-injectable long-acting HIV therapy; FB2001, a SARS-CoV-2 3CL protease inhibitor under clinical development for hospitalized patients as well as for post-exposure prophylaxis of Covid-19; FB3001, a new transdermal topical patch for musculoskeletal joint pain treatment under clinical development; and FB600, an investigational therapeutic peptide vaccine targeting PCSK9 to treat hypercholesterolemia. The company was founded in 2013 and is headquartered in Nanjing, China.
Name | Age | Since | Title |
---|---|---|---|
Rongjian Lu | 61 | 2016 | CTO & Director |
Dong Xie | 57 | 2002 | Founder, Chairman & Chief Scientific Officer |
Chi Kit Ng | 49 | 2019 | Independent Director |
Xian Wang | 56 | 2019 | Independent Director |
Kai Chen | 64 | 2019 | Independent Director |
Zhi Zhong Jiang | 41 | 2016 | Chairman of the Supervisory Board & Deputy Director of Material Control |
Honghai Wen | 58 | 2018 | Director |
Changjin Wang | 65 | 2016 | CEO & Director |
Yuting Zhu | 35 | 2019 | Supervisor & Deputy Administrative Director |
Yuantao Cao | 43 | 2018 | Supervisor |
Guangji Wang | 71 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review